NI-0101

Light Chain Bioscience - Novimmune SA · Phase 2 active Small molecule

At a glance

Generic name	NI-0101
Sponsor	Light Chain Bioscience - Novimmune SA
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study of an Anti-TLR4 mAb in Rheumatoid Arthritis (PHASE2)
First in Human Study of an Anti-Toll-like Receptor 4 (TLR4) Monoclonal Antibody (NI-0101) in Adult Healthy Volunteers (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

NI-0101 CI brief — competitive landscape report
NI-0101 updates RSS · CI watch RSS
Light Chain Bioscience - Novimmune SA portfolio CI